At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 115 enrolled
Drug / intervention
Dexlansoprazole +2 moredrug
Likely dose
Dexlansoprazole 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Dexlansoprazole 60 mg Delayed Release Capsules and Esomeprazole 40 mg Delayed Release Capsules on Bone Homeostasis in Healthy Postmenopausal Female Subjects
In Brief
A Phase 1 clinical trial evaluating Dexlansoprazole, Esomeprazole, and 1 other intervention for Homeostasis and Bone and Bones. Completed, enrolled 115 participants across 12 sites.
Detailed Summary
The purpose of this study is to evaluate the effect of dexlansoprazole modified release (MR), once daily (QD), on bone homeostasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHomeostasis, Bone and Bones
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartNov 2010
Primary CompletionAug 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedOct 7, 2010
Enrollment StartNov 1, 2010
Primary CompletionAug 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 15.7 years ago
Interventions
Dexlansoprazoledrug
Dexlansoprazole 60 mg capsules
Esomeprazoledrug
Esomeprazole 40 mg capsules
Placebodrug
Placebo-matching capsules